title: A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.
abstract: Chronic total coronary occlusions constitute a sub-group of lesions at very high risk of restenosis after successful percutaneous coronary intervention. The sirolimus-eluting coronary stent is the only drugeluting stent that has demonstrated to reduce angiographic restenosis and the need for new revascularisation procedures in comparison with bare-metal stents in randomised clinical trials focusing on these lesions. Everolimus-eluting stents have shown to offer optimal angiographic and clinical outcomes in comparison with bare-metal stents and paclitaxel-eluting stents, but no randomised trials have tested the device in chronic total occlusions. The CIBELES (non-acute Coronary occlusIon treated By EveroLimus- Eluting Stent) will randomise 208 patients with chronic total coronary occlusions in 13 centres from Portugal and Spain to receive everolimus- or sirolimus-eluting coronary stents. The primary endpoint will be angiographic in-stent late loss.
authors.affiliation: University Hospital La Paz, Madrid, Spain. raulmorenog@terra.es
authors.forename: Raúl
authors.initials: R
authors.lastname: Moreno
authors.forename: Eulogio
authors.initials: E
authors.lastname: Garcia
authors.forename: Rui C
authors.initials: RC
authors.lastname: Teles
authors.forename: Manuel S
authors.initials: MS
authors.lastname: Almeida
authors.forename: Henrique Cyrne
authors.initials: HC
authors.lastname: Carvalho
authors.forename: Manel
authors.initials: M
authors.lastname: Sabate
authors.forename: Roberto
authors.initials: R
authors.lastname: Martin-Reyes
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Rumoroso
authors.forename: Guillermo
authors.initials: G
authors.lastname: Galeote
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Goicolea
authors.forename: José
authors.initials: J
authors.lastname: Moreu
authors.forename: Vicente
authors.initials: V
authors.lastname: Mainar
authors.forename: Josefa
authors.initials: J
authors.lastname: Mauri
authors.forename: Rui
authors.initials: R
authors.lastname: Ferreira
authors.forename: Mariano
authors.initials: M
authors.lastname: Valdes
authors.forename: Armando
authors.initials: A
authors.lastname: Perez de Prado
authors.forename: Victoria
authors.initials: V
authors.lastname: Martin-Yuste
authors.forename: Santiago
authors.initials: S
authors.lastname: Jimenez-Valero
authors.forename: Angel
authors.initials: A
authors.lastname: Sanchez-Recalde
authors.forename: Luis
authors.initials: L
authors.lastname: Calvo
authors.forename: Esteban
authors.initials: E
authors.lastname: Lopez de Sa
authors.forename: Carlos
authors.initials: C
authors.lastname: Macaya
authors.forename: Jose-Luis
authors.initials: JL
authors.lastname: Lopez-Sendon
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000209:etiology; D054855:Drug-Eluting Stents; D000068338:Everolimus; D006801:Humans; D011174:Portugal; D011474:Prosthesis Design; D012107:Research Design; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus